Alliance Pharma PLC (LSE:APH)

£ 0.352 0.009 (2.62%) Market Cap: 190.22 Mil Enterprise Value: 288.54 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 69/100

Half Year 2023 Alliance Pharma PLC Earnings Call Transcript
Sep 26, 2023

£0.484 (+2.33%)

Earnings
Full Year 2022 Alliance Pharma PLC Earnings Call Transcript
Mar 21, 2023

£0.584 (+1.39%)

Earnings
Half Year 2022 Alliance Pharma PLC Earnings Call Transcript
Sep 20, 2022

£0.673 (-9.30%)

Earnings
Preliminary 2021 Alliance Pharma PLC Earnings Call Transcript
Mar 22, 2022

£1.13 (+1.62%)

Earnings
Half Year 2021 Alliance Pharma PLC Earnings Presentation - Pre-Recorded Transcript
Sep 21, 2021
Half Year 2021 Alliance Pharma PLC Earnings Call - Q&A Session Transcript
Sep 21, 2021

£1.05 (+3.56%)

Earnings
Full Year 2020 Alliance Pharma PLC Earnings Call Transcript
Mar 23, 2021

£0.878 (+3.42%)

Earnings
Half Year 2020 Alliance Pharma PLC Earnings Call Transcript
Sep 22, 2020

£0.737 (+0.96%)

Earnings
Alliance Pharma PLC Annual Shareholders Meeting Transcript
May 18, 2020
Full Year 2019 Alliance Pharma PLC Earnings Call Transcript
Apr 07, 2020

£0.694 (+11.94%)

Earnings
Half Year 2019 Alliance Pharma PLC Earnings Call Transcript
Sep 24, 2019

£0.732 (+0.83%)

Earnings
Full Year 2018 Alliance Pharma PLC Earnings Call Transcript
Mar 26, 2019

£0.68 (+5.26%)

Earnings

Half Year 2022 Alliance Pharma PLC Earnings Call Transcript

Sep 20, 2022 / 08:30AM GMT

Release Date Price: £0.673 (-9.30%)

Transcript

Peter Jonathan Butterfield

Alliance Pharma plc - CEO & Executive Director

Good morning, everybody, and welcome to the Alliance 2022 Interim Results Presentation. I'm pleased to see so many of you in-person this morning and look forward to meeting those who are listening on the webcast very soon.

As always, this morning, I'm joined by Andrew Franklin, our CFO; and Cora McCallum, our Head of Investor Relations and Corporate Communications.

Turning our attention to today's presentation. I'll begin with a reminder of our strategy and how this has supported our progress in the first half of 2022 before handing over to Andrew to walk you through the detail of the results.

I'll also touch briefly on the CMA case, as much as I'm able to do so in terms of timings and what happens next. I'll then finish with the summary and a reminder of the outlook for the remainder of the year before opening the floor to questions.

This slide serves as a reminder of our strategy. We're committed to delivering solid organic growth through investment in marketing excellence supported by

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.